drugset

drugset / Trial / NCT04733508

Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes

NCT04733508 ↗

Unknown 28 enrolled Radboud University Medical Center University of Coimbra · collab

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes

Timeline

Start: 2019-11-01
Primary completion: 2022-06-01
Completion: 2022-12-01

Publications

Jansen TJP, Tokgoz S, Buitinga M, van Lith SAM, Joosten L, Frielink C, Smeets EMM, Stommel MWJ, van der Kolk MB, de Galan BE, Brom M, Boss M, Gotthardt M. Validation of radiolabelled exendin for beta cell imaging by ex vivo autoradiography and immunohistochemistry of human pancreas. EJNMMI Res. 2024 Oct 15;14(1):96. doi: 10.1186/s13550-024-01159-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	111In-DTPA-exendin-4	Diagnostic / imaging agent	—	Other
Subject	IRDye800CW-exendin-4	Diagnostic / imaging agent	—	Other

Indications